CD8A and neoplasm: A monoclonal antibody targeting CSF-1R depleted TAMs and increased the CD8+/CD4+ T cell ratio, leading to decreased primary tumor burden and decreased metastasis in mouse models of colorectal cancer and fibrosarcoma [53].